“The focus of this grant is understanding the role that cell types play in skin, muscle, and blood inflammation to identify new markers and better treatments for JM patients during all phases of the disease,” says Dr. Turnier. “Once we better understand what happens at the cellular level, we may be able to target therapies to those very cells.” 

“Cure JM’s role will be to foster collaboration across our Centers of Excellence and Clinical Care Network,” Dr. Heaton adds. “The evaluators were impressed with the breadth of our organization and the importance of engaging a significant number of JM families from diverse backgrounds in this project. We’re thrilled with Chan Zuckerberg’s confidence in Cure JM.”